bioRxiv · 10.1101/2022.09.01.506264
An Engineered T7 RNA Polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis
Abstract
Messenger RNA (mRNA) therapies have recently gained tremendous traction with the approval of mRNA vaccines for the prevention of SARS-CoV-2 infection. However, manufacturing challenges have complicated large scale mRNA production, which is necessary for the clinical viability of these therapies. Not only can the incorporation of the required 5 7-methylguanosine cap analog be inefficient and costly, in vitro transcription (IVT) using wild-type T7 RNA polymerase generates undesirable double-stranded RNA (dsRNA) byproducts that elicit adverse host immune responses and are difficult to remove at large scale. To overcome these challenges, we have engineered a novel RNA polymerase, T7-68, that co-transcriptionally incorporates both di- and tri-nucleotide cap analogs with high efficiency, even at reduced cap analog concentrations. We also demonstrate that IVT products generated with T7-68 have reduced dsRNA content.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Miller, M., Alvizo, O., Chng, C., Jenne, S., Mayo, M., Mukherjee, A., Sundseth, S., Chinthala, A., Penfield, J., Riggins, J., Zhang, S., Sero, A., Dassie, J., Leatherbury, N., Baskerville, S., Huisman, G.. 2022-09-02. An Engineered T7 RNA Polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis. https://doi.org/10.1101/2022.09.01.506264
Cite the original work for its findings. Save a collection to share your selection of sources.